350 likes | 357 Views
In the name of God. Mesenchymal stem cell therapy in Neonates Shahid Beheshti medical university mofid Children Hospital Bibi shahin shamsian. Mesenchymal cell therapy in Neonates. Introduction.
E N D
In the name of God Mesenchymal stem cell therapy in Neonates Shahid Beheshti medical university mofid Children Hospital Bibishahinshamsian
Introduction • Despite recent advances in Neonatal Medicine, Neonatal disorders: Bronchopulmonary dysplasia (BPD) Intraventricular (IVH ) in preterm neonates & Hypoxic ischemic Encephalopathy in term neonates :Major causes of Mortality & Morbidities. • Promising preclinical research results suggest: • Stem Cell Therapies represent the next breakthrough in the treatment of currently intractable and devastating neonatal disorders with complex Multifactorial Etiologies.
Stem cells Cell Therapy & Regenereative Medicine • Stem cells , Naivecells-Specialized cell: • Renewing themselves • Differentiate into multi-lineage cells • Stem cell Classification: • Embryonic Stem Cells (ESCs) • Induced Pluripotent Stem Cells (I-PSCs) • Adult Stem Cells Xin WEI1 .ActaPharmacologicaSinica (2013) 34: 747–754
Embryonic stem cells (ESCs) &Induced pluripotent stem cells (iPSCs) ESCs ESC: Pluripotent stem cells; Inner cell mass of a blastocyst, an early-stage pre- implantation Embryo IPSCs : Adult Somatic Cells :Reprogrammed to an Embryonic Stem Cell-like state by enforced expression of pluri potency transcription factors Risks: Ethical issues & Teratoma potential
Stem cell ClassificationAdult Stem Cells Classification Adult Stem cells • Adult Stem Cells: • Hematopoietic Stem Cells (HSC) • Mesenchymal Stem Cells(MSC) • ….
Mesenchymal stem cell • Non-Haematopoietic • Maintenance of Bone Marrow Homeostasis • Multipotent stem cells • (Osteoblasts, Adipocytes, & Chondroblasts) • Free of both Ethical concerns & Teratoma potential Xin WEI1 .ActaPharmacologicaSinica (2013) 34: 747–754
Definition of an MSC :International Society for Cellular Therapy in 2006 .( 3 criteria) Minimal criteria of Mesenchymal Stem Cells.Korean Journal of Internal Medicine Vol. 28, No. 4, July 2013
Sources MSC • MSCs exist in almost all tissues: • Bone marrow (BM-MSCs) • umbilical cord blood (UCB-MSCs) • Wharton’s jelly • Placenta (P-MSCs) • Amniotic fluid (AF-MSCs) • Adipose tissue (ADSCs) • Exfoliated deciduous teeth Xin WEI1 .ActaPharmacologicaSinica (2013) 34: 747–754 SylwiaBobis. FOLIAHISTOCHEMICA ETCYTOBIOLOGICA Vol. 44, No. 4, 2006 Yonsei. Med J. 2017 Mar 1 ;58(2)266-271Stem cell therapy for neonatal Disorers
Placenta-Derived and Amniotic Fluid-Derived MSCs BM-MSCs have been the“Gold standard,” Fetal sources ;(21.1%) umblical cord blood,placenta UC/UCB-MSCs may be a “platinum standard. Wang et al. Journal of Biomedical Science (2016) 23:76
Gestational tissues, rather than adult tissues, might be a promising source for obtaining exogenous human MSCs for future clinical use in treating neonates with intractable disorders • MSCs (Gestational tissues): • Easy Obtainability • No significant Ethical Concerns • Lower Immunogenicity • Higher Proliferative Capacity • Paracrine Potency > Adult Tissue Mueller et al. Molecular and Cellular Pediatrics (2016) 3:6 YunSilChang.Yonsei Med J 2017 Mar;58(2):266-271
Mode of action of MSCs as cell therapy agents • The Clinical use of MSCs :Biological characteristics • 4 properties of MSCs in clinical uses: • Ability to differentiate into various cell types • Ability to migrate to sites of inflammation when injected intravenously • Ability to secrete multiple bioactive molecules capable of inhibiting inflammation and healing injured cells • Ability to perform immunomodulatory functions while lacking immunogenicity BrunaAmorin •Human Cell (2014) 27:137–150
Mesenchymal Stem Cell Therapy for Pediatric Disease: Perspectives on Success and Potential Improvements • 1980s - Arnold Caplan, MSC-based therapy have As an extremely promising therapy in Adult medicine, and then pediatric • MSCs :Represent a potentially revolutionary therapy for a wide variety of pediatric diseases including Neonates CHRISTOPHER R. NITKIN Mese Ohio, USA STEM CELLS TRANSLATIONAL MEDICINE 2017;5:1–27 w.
The Central Question to MSC therapy • Question is not:“Are MSCs therapeutically effective?” • Rather,it is: “How can we optimize MSC therapy for efficacy While avoiding Adverse Efects?” • Optimize the therapeutic application of MSCs, including in the pediatric population CHRISTOPHER R Nitkin. STEM CELLS TRANSLATIONAL MEDICINE 2017;5:1–27 Cleveland, Ohio, USA
Clinical Trials / MSC • NIH Clinical trial Database- APR 2016 > 500 MSC related clinical trials • > Half (42%) in Immune/ Inflamation mediated disease • Most Evaluation : • Phase 1 or 2( Safety and Efficacy) • small nu phase 3 • Just , 1 phase 4 trial, for Side Effectss after Marketing CHRISTOPHER R Nitkin. STEM CELLS TRANSLATIONAL MEDICINE 2017;5:1–27 Cleveland, Ohio, USA
Clinical phases of mesenchymal stem cells-based therapy. Data from Clinical Trials.gov. Xin WEI1 .ActaPharmacologicaSinica(2013) 34: 747–754
pediatric Diseases/ MSC • Neonates: • Bronchopulmonary Dysplasia( Neonates) • Severe Intraventricular Hemorrhage (IVH) • Hypoxic Ischemic Encephalopathy (HIE) • Periventricularleukomalacia (PVL). • Phase I clinical trials (MSC -Neonates) :BPD, HIE, severe IVH :Safe, Feasible, potentially Efficacious
Stem Cell Therapy for Neonatal Diseases Associated with Preterm BirthAlessandro Borghes. J ClinNeonatol. 2013 Jan-Mar; 2(1): 1–7 • Neonatal Medical Care: Increased survival of VLBW infants, , extends to 22 weeks Gestational Age • Extreme preterm birth : significant morbidity short-term & long-term pulmonary complications • Broncho pulmonary dysplasia- BPD up to 43% of infants , BW< 1500 g • Neurologic : • PeriventricularLeukomalacia (PVL )
Stem Cell Therapy for Neonatal Diseases Associated with Preterm BirthAlessandro Borghes. J ClinNeonatol. 2013 Jan-Mar; 2(1): 1–7 • Mechanisms underlying tissue simplification is still incomplete?? • Directly Damaging of Stem/Progenitor cells, by Combination of Risk factors including : • Oxidative stress- ROS and RNS • Genetic predisposition • Deprivation of maternal/placental molecules
Stem Cell Therapy for Neonatal Diseases Associated with Preterm BirthAlessandro Borghes. J ClinNeonatol. 2013 Jan-Mar; 2(1): 1–7 Common mechanisms of pathogenesis in diverse diseases of prematurity Common mechanisms of pathogenesis in diverse diseases of prematurity
Clinical trial In Neonates • Phase I clinical trial for BPD • Phase I clinical trial for HIE • Phase I clinical trial for IVH Mueller et al. Molecular and Cellular Pediatrics (2016) 3:6 YunSilChang.YonseiMed J 2017 Mar;58(2):266-271 Maria Pierro1Mesenchymal stem cells for the prevention and treatment of b ronchopulmonary dysplasia in preterm infants (Protocol).2015
Chang, et al;Phase I clinical trial for BPD • single intratracheal (IT) transplantation of Allogenic human umbilical cord blood (UCB)-derived MSCs for BPD. • 9 very preterm infants at high risk , BPD mean GA 25 weeks (range: 24–26 weeks) & a mean birth weight of 793 g (range: 630–1030 g) at a mean age of 10 days (range: 7–14 days) after birth. • all on continuous ventilator support with no signs of imminent clinical improvement. • 3 low dose (1×107 cells/kg in 2 mL/kg of saline), 6 high dose (2×107 cells/kg in 4 mL/kg of saline). • MSCs intratracheally in 2 fractions into the left and right lungs via a gavage tube • well tolerate,without any serious adverse effects or doselimiting toxicity up to 84 days • No significant differences in serious adverse effects were observed between the low- and high-dose groups. • Levels of cytokines in tracheal aspirates at day 7 following treatment were significantly reduced, compared with those at baseline. • Furthermore, BPD severity was significantly lower in transplant recipients, compared with the historical gestational age-, birth weight-, and respiratory severity score-matched control group. • A long-term follow-up study and a phase II, double-blind, randomized, controlled trial to assess therapeutic efficacy are underway. YunSilChang.Yonsei Med J 2017 Mar;58(2):266-271
Broncho pulmonary dysplasia/MSC • First Clinical trial of MSCs in neonates for BPD :2014 • PNEUMOSTEM, Allogeneic human UCB-MSC product(expanded exvivo in FBS to passage 6), ,dose-escalation study (1–2 x 107 cells /kg) via Endotracheal tube to 5- 14-day-old extremely preterm neonates -at 27 weeks -or younger. • Ttreated :less severe BPD ,reduced levels of inflammation,and no treatment-related adverse effects Ciprianp.Stem Cell Therapy in Neonatal Disease.2015s CHRISTOPHER R Nitkin. STEM CELLS TRANSLATIONAL MEDICINE 2017;5:1–27 Stem cells for brain repair in neonatal hypoxia–ischemia.L. Chicha
Phase I clinical trial for IVHYonsei Med J 2017 Mar;58(2):266-271 Human UCB-derived MSC transplantation in preterm infants with severe IVH (i.e., grade≥3) Safety & feasibility of a single intraventricular -Allogenic human UCB-derived MSCs within 7 days after detection of severe IVH (grade≥3) under ultrasound guidance in preterm infants. 9 preterm infants - severe IVH, 3 were given a low dose (5×106 cells/kg in 1 mL/kg of saline); 6 infants were given a high dose (1×107 cells/kg in 2 mL/kg of saline. Infants are currently undergoing follow-up care for long-term adverse outcomes and assessment of neurologic health YunSilChang.Yonsei Med J 2017 Mar;58(2):266-271
Phase I clinical trial for HIECotten, et al Autologous UCB cell transplantation in a phase I clinical trial 23 neonates with HIE ,concurrent hypothermia treatment. IV infusion of non-cryopreserved, Autologous, up to four doses of 1– 5×107 cells per dose Feasible & well tolerated. No significant adverse reactions, Cardiopulmonary compromise, or Infections UCB recipients- better 1-year survival rates (74%) than concurrent cooled infants (41%) Randomized, double-blind, controlled clinical trials in the future will be required YunSilChang.Yonsei Med J 2017 Mar;58(2):266-271
PROSPECTS AND CHALLENGES FOR CLINICAL TRANSLATION • CHALLENGES • Right patients: High risk • Right Cells: Auto versus Allo MSC • Right Route: Systemic versus Localized • Right Timing: Early Vs late • Right Dose:??? • Safety of MSC Transplantation( GMP) CHRISTOPHER R Nitkin.STEM CELLS TRANSLATIONAL MEDICINE 2017.5:1–27 YunSilChang.Yonsei Med J 2017 Mar;58(2):266-271
Right Patients • Newborn infants at highest risk for developing intractable diseases • Mortality & Morbidities • Gestational Age • prolonged Respiratory support • Additional clinical predictors and/or Biomarkers
AllO Vs AUTO MSC • Autologous MSC: %32.5 • Allogenic MSC: %50 • MSCs : • Weak expression of MHC class I • Absent MHC class II markers • “Off-the-Shelf ”:Allogeneic product- Healthy Donor ? • BPD trial could be administered within the first few minutes of life or within hours of diagnosis Wang et al. Journal of Biomedical Science (2016) 23:76
Right Route • Local : Intaratheraceal, Intrathecal, Intranasal • systemic: Intraperitoneal -Intravenous • systemic: • Minimally-Invasive • Limitations in crossing the blood brain barrier(BBB) • Retain in other organs, such as the lungs, liver, spleen, and kidneys • 4 to 5,Fold Higher Doses
Right Time • Therapeutic time window for stem cell therapy might be narrow • Further studies will be necessary to clarify this
Right Dose • Factors: • Underlying disease & Severity • Route of Administration. • phase I clinical trial for severe IVH; • No dose limiting toxicity or serious adverse events were observed with either dose.
Good Manufacturing Practice • Safety of MSC transplantation • High-quality • Standardized • Absence of Adverse Effects • MSC exert their therapeutic function by a “Hit and Run” mechanism • Absence of Adverse Effects including Tumorigenicity duo to Absent Engraftment of the transplanted MSCs
Before large-scale translation into the clinical arena ,however factors such as cell source, culture conditions, donor factors, recipient factors, and ex vivo differentiation must be addressed CHRISTOPHER R Nitkin. STEM CELLS TRANSLATIONAL MEDICINE 2017;5:1–27
Conclusion • Energy and attention ;to detail that will optimize the therapeutic application of MSCs in the pediatric population including Neonates • Essential to proceed Step by step rather than haste